Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 23 04:00PM ET
15.65
Dollar change
+0.57
Percentage change
3.78
%
IndexRUT P/E- EPS (ttm)-1.57 Insider Own32.59% Shs Outstand70.45M Perf Week-5.89%
Market Cap1.46B Forward P/E- EPS next Y-2.05 Insider Trans2.04% Shs Float62.97M Perf Month-3.69%
Income-100.16M PEG- EPS next Q-0.39 Inst Own64.12% Short Float9.09% Perf Quarter1.23%
Sales0.00M P/S- EPS this Y-8.84% Inst Trans17.24% Short Ratio7.44 Perf Half Y129.14%
Book/sh4.53 P/B3.46 EPS next Y-19.06% ROA-28.33% Short Interest5.72M Perf Year105.38%
Cash/sh3.41 P/C4.59 EPS next 5Y- ROE-30.10% 52W Range5.12 - 20.69 Perf YTD43.05%
Dividend Est.- P/FCF- EPS past 5Y-68.02% ROI-30.98% 52W High-24.36% Beta0.25
Dividend TTM- Quick Ratio19.50 Sales past 5Y0.00% Gross Margin- 52W Low205.66% ATR (14)1.02
Dividend Ex-Date- Current Ratio19.50 EPS Y/Y TTM-24.21% Oper. Margin0.00% RSI (14)43.74 Volatility6.40% 6.42%
Employees88 Debt/Eq0.02 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price32.60
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-51.60% Payout- Rel Volume0.72 Prev Close15.08
Sales Surprise- EPS Surprise-8.10% Sales Q/Q- EarningsFeb 22 BMO Avg Volume769.40K Price15.65
SMA20-6.12% SMA50-8.05% SMA20050.37% Trades Volume557,752 Change3.78%
Date Action Analyst Rating Change Price Target Change
Mar-07-24Initiated Piper Sandler Overweight $48
May-01-23Initiated Truist Buy
Aug-25-22Downgrade Goldman Neutral → Sell $5
Apr-13-22Initiated RBC Capital Mkts Outperform $31
Jan-28-22Initiated Goldman Neutral $11
Apr-23-24 09:34AM
08:00AM
Apr-15-24 04:05PM
Mar-28-24 08:00AM
Mar-27-24 08:00AM
08:00AM Loading…
Mar-05-24 08:00AM
Feb-28-24 08:00AM
Feb-26-24 09:55AM
Feb-22-24 08:00AM
Feb-21-24 09:21AM
Feb-13-24 08:00AM
Feb-11-24 02:55PM
Feb-09-24 09:55AM
Jan-25-24 10:04PM
Jan-24-24 09:55AM
02:06PM Loading…
Jan-22-24 02:06PM
Jan-19-24 08:37AM
Jan-16-24 09:00AM
Jan-09-24 08:39AM
Dec-29-23 11:02PM
Dec-19-23 08:00AM
Dec-18-23 08:00AM
Nov-30-23 08:00AM
Nov-28-23 07:29AM
Nov-09-23 09:41AM
08:00AM
Nov-08-23 08:00AM
Nov-01-23 08:00AM
Oct-26-23 08:00AM
Oct-10-23 09:55AM
08:00AM Loading…
Sep-27-23 08:00AM
Sep-26-23 08:00AM
Sep-14-23 08:00AM
Sep-05-23 09:55AM
Aug-31-23 10:12PM
Aug-16-23 09:55AM
Aug-10-23 08:00AM
Jul-17-23 12:51PM
Jun-27-23 09:43AM
Jun-26-23 04:01PM
Jun-06-23 08:00AM
May-11-23 08:00AM
May-02-23 08:00AM
Mar-30-23 04:01PM
Mar-21-23 08:00AM
Mar-14-23 08:00AM
Mar-06-23 08:00AM
Mar-01-23 08:00AM
Feb-28-23 08:00AM
Feb-23-23 08:00AM
Feb-07-23 09:39AM
08:00AM
Jan-04-23 08:30AM
Dec-21-22 09:00AM
Dec-20-22 09:00AM
Nov-14-22 09:55AM
Nov-09-22 08:00AM
Nov-03-22 08:00AM
Oct-27-22 04:05PM
Oct-25-22 12:00PM
09:55AM
Oct-13-22 04:30PM
Oct-06-22 08:00AM
Sep-23-22 06:35PM
Sep-16-22 04:05PM
Sep-13-22 09:17PM
05:04PM
08:49AM
Sep-11-22 05:00PM
Sep-07-22 08:00AM
Aug-31-22 08:30AM
Aug-04-22 08:00AM
Aug-03-22 08:00AM
Jul-18-22 11:44AM
Jul-12-22 08:00AM
Jun-22-22 01:53PM
Jun-21-22 08:47AM
Jun-20-22 08:00AM
Jun-16-22 08:00AM
May-31-22 08:00AM
May-11-22 08:00AM
May-03-22 08:00AM
Apr-28-22 11:45AM
Apr-14-22 08:00AM
Mar-24-22 11:11AM
Mar-08-22 08:00AM
Feb-24-22 08:00AM
Feb-03-22 04:35PM
Feb-02-22 09:00AM
Jan-10-22 07:40PM
Jan-05-22 09:15AM
08:00AM
Dec-15-21 09:00AM
Nov-17-21 09:00AM
Nov-10-21 08:00AM
Nov-04-21 11:23AM
Oct-28-21 07:29AM
06:00AM
Oct-11-21 03:56PM
Oct-06-21 11:45AM
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MOORE JOHN RGeneral CounselFeb 09 '24Option Exercise1.938,02915,4968,029Feb 09 05:43 PM
Derakhshan BehradChief Business OfficerFeb 09 '24Option Exercise1.934,8009,26411,820Feb 09 05:42 PM
MOORE JOHN RGeneral CounselFeb 09 '24Sale20.018,029160,6570Feb 09 05:43 PM
Derakhshan BehradChief Business OfficerFeb 09 '24Sale20.044,80096,2097,020Feb 09 05:42 PM
Derakhshan BehradChief Business OfficerFeb 08 '24Option Exercise1.934,6008,87811,620Feb 09 05:42 PM
MOORE JOHN RGeneral CounselFeb 08 '24Option Exercise1.933,8137,3593,813Feb 09 05:43 PM
Derakhshan BehradChief Business OfficerFeb 08 '24Sale20.014,60092,0497,020Feb 09 05:42 PM
MOORE JOHN RGeneral CounselFeb 08 '24Sale20.013,81376,2850Feb 09 05:43 PM
MOORE JOHN RGeneral CounselFeb 07 '24Option Exercise1.9317,99334,72617,993Feb 09 05:43 PM
Derakhshan BehradChief Business OfficerFeb 07 '24Option Exercise1.936001,1587,620Feb 09 05:42 PM
MOORE JOHN RGeneral CounselFeb 07 '24Sale20.0017,993359,8640Feb 09 05:43 PM
Derakhshan BehradChief Business OfficerFeb 07 '24Sale20.0060012,0007,020Feb 09 05:42 PM
Carruthers R MichaelChief Financial OfficerJan 23 '24Option Exercise1.9390,000173,700119,024Jan 25 04:46 PM
ORBIMED ADVISORS LLCDirectorJan 23 '24Buy11.00454,5454,999,99514,436,497Jan 25 04:28 PM
Thompson Peter A.DirectorJan 23 '24Buy11.00454,5454,999,99514,436,497Jan 25 04:32 PM
Carruthers R MichaelChief Financial OfficerJan 23 '24Sale15.7890,0001,419,75929,024Jan 25 04:46 PM
MOORE JOHN RGeneral CounselDec 27 '23Sale10.508,49789,2180Dec 28 04:39 PM
Fox Jonathan CDirectorDec 26 '23Buy9.3010,857100,95810,857Dec 28 04:39 PM
Russell Alan JChief Scientific OfficerDec 26 '23Sale9.33172,5851,610,0973,606Dec 28 04:38 PM
Carruthers R MichaelChief Financial OfficerJun 22 '23Option Exercise0.7110,0007,10029,024Jun 26 04:28 PM
Donovan Joanne M.CMOMay 02 '23Sale8.903,25428,9779,960May 03 06:25 PM
KOCH KEVINPresident and CEOMay 02 '23Sale8.903,20328,5227,213May 03 06:25 PM
MOORE JOHN RGeneral CounselMay 02 '23Sale8.901,89716,8936,565May 03 06:26 PM
Derakhshan BehradChief Business OfficerMay 02 '23Sale8.901,74715,5577,020May 03 06:26 PM
Russell Alan JChief Scientific OfficerMay 02 '23Sale8.901,60214,266176,191May 03 06:26 PM
Carruthers R MichaelChief Financial OfficerMay 02 '23Sale8.901,33611,89716,126May 03 06:26 PM
Carruthers R MichaelChief Financial OfficerMay 01 '23Option Exercise0.005,208017,462May 03 06:26 PM
Russell Alan JChief Scientific OfficerMay 01 '23Option Exercise0.005,2080177,793May 03 06:26 PM
MOORE JOHN RGeneral CounselMay 01 '23Option Exercise0.005,20808,462May 03 06:26 PM
Derakhshan BehradChief Business OfficerMay 01 '23Option Exercise0.005,20808,767May 03 06:26 PM
KOCH KEVINPresident and CEOMay 01 '23Option Exercise0.0010,416010,416May 03 06:25 PM
Donovan Joanne M.CMOMay 01 '23Option Exercise0.0010,416013,214May 03 06:25 PM